No Data
Beijing Beilu Pharmaceutical (300016.SZ): Obtained the pharmaceutical registration certificate for the silicone oil emulsion.
On February 7, Gelonghui reported that Beijing Beilu Pharmaceutical (300016.SZ) announced that it has recently received the drug registration certificate for simethicone emulsion issued by the National Medical Products Administration. Simethicone emulsion, developed by Berlin-Chemie AG in Germany, is an oral nanoemulsion commonly used as an anti-foaming agent in clinical settings, indicated for: (1) treating discomfort symptoms caused by excessive gas accumulation in the gastrointestinal tract, such as abdominal distension, and can also be used post-operatively; (2) serving as an auxiliary medication for abdominal imaging examinations (e.g., X-ray, ultrasound, gastroscopy) and as a double contrast agent.
Beijing Beilu Pharmaceutical (300016.SZ): Golden Lotus Flower granules are expected to be selected for centralized bulk procurement of Chinese Patent Medicine such as Guangdong Alliance Golden Lotus Flower capsules.
On February 5, Gelonghui reported that Beijing Beilu Pharmaceutical (300016.SZ) announced that its holding subsidiary, Chengde Tianyuan Pharmaceutical Co., Ltd. (referred to as "Tianyuan Pharmaceutical"), participated in the centralized bulk procurement work for Chinese Patent Medicine, including Guangdong Alliance gold lotus flower capsules. According to the notice released by the Guangdong Provincial Pharmaceutical Trade Center regarding the proposed selection results for the centralized bulk procurement of Chinese Patent Medicine like Guangdong Alliance gold lotus flower capsules, Tianyuan Pharmaceutical's gold lotus flower granules are set to be selected for this procurement.
Beijing Beilu Pharmaceutical (300016.SZ) announces a pre-profit report, expecting an annual net income of 9.5 million yuan to 12.5 million yuan.
Beijing Beilu Pharmaceutical (300016.SZ) disclosed its performance forecast for 2024, with Net income attributable to shareholders of the listed company...
Hokuriku Pharmaceutical: 2024 performance forecast
Beijing Beilu Pharmaceutical (300016.SZ): Renewed the concerted action agreement.
On December 16, Glonghui reported that Beijing Beilu Pharmaceutical (300016.SZ) announced that the company has recently renewed the "Joint Action Agreement" with Ms. Zeng Chunhui, the second largest Shareholder of Haichang Pharmaceutical. This renewal of the "Joint Action Agreement" has not led to a change in the actual control of Haichang Pharmaceutical, and the controlling Shareholder of Haichang Pharmaceutical remains the company. The renewal of the "Joint Action Agreement" is beneficial for the company to maintain the stability of the actual control of its holding subsidiary Haichang Pharmaceutical, ensuring consistency in major decision-making matters at Haichang Pharmaceutical, and is favorable for the coherence and stability of the company's Global Strategy and Operations management, and will not have an impact on the daily operations management of the company and Haichang Pharmaceutical.
beijing beilu pharmaceutical (300016.SZ) obtained GMP certification from the Brazilian National Health Surveillance Agency.
Beijing Beilu Pharmaceutical (300016.SZ) announced that recently, the company has obtained approval from the Brazilian National Health Surveillance Agency ("ANVISA")...
